Abstracts tagged "Myositis"

Abstract Number: 1065 • ACR Convergence 2020
Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis
Adarsh Ravishankar¹, Daisy Yan², Christina Bax³, Josef Symon Concha², Bridget Shields⁴, Lisa Pappas-Taffer⁴, Rui Feng⁵, Joyce Okawa⁴ and Victoria Werth², ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³University of Pennsylvania, Department of Dermatology, Philadelphia, ⁴Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia
Background/Purpose: The use of complementary and alternative medicine (CAM) is prevalent in dermatology. Certain CAMs, including Spirulina, Alfalfa, Chlorella, Echinacea, and Blue-Green Algae have been…
Abstract Number: 1086 • ACR Convergence 2020
The Diagnostic Value and Clinical Significance of Myositis-Specific Antibodies in Patients Suspected to Have Autoimmune Myopathies and/or Autoimmune Rheumatic Diseases
Sarah El Chami¹, Christopher Williams¹, Ghaith Noaiseh¹, Amrita Bath¹ and Duaa Jabari¹, ¹The University of Kansas Health System, Kansas city, KS
Background/Purpose: Myositis-specific antibodies (MSA) are thought to be highly specific in patients with idiopathic inflammatory myopathies.[1] However, in clinical practice these antibodies are frequently found…
Abstract Number: 1916 • ACR Convergence 2020
KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model
Marta Del Rio Oliva¹, Michael Basler¹, Darrin Bomba², Diana Lam², Jennifer Brandl², Christopher Kirk² and Marcus Groettrup¹, ¹University of Konstanz, Konstanz, Germany, ²Kezar Life Sciences, Inc, San Francisco, CA
Background/Purpose: Polymyositis (PM) is a chronic autoimmune inflammatory myopathy affecting striated muscles and resulting in muscle weakness. PM is a rare disease, and there are…
Abstract Number: 1066 • ACR Convergence 2020
Prevalence of Cervical Dysplasia in Women with Antisynthetase Syndrome
Alexis Katz¹, Yuxuan Jin¹ and Soumya Chatterjee², ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Increased risk of cervical dysplasia and cervical cancer have been reported in patients with systemic lupus erythematosus (SLE). However, the reason for this increased…
Abstract Number: 1088 • ACR Convergence 2020
Recruitment Rates of Virtual Remote Research (Tele-Research) in Myositis
Siamak Moghadam-Kia¹, Chester Oddis², Swamy Venturupalli³, Shalini Mahajan⁴, Daphne Scaramangas Plumley⁵, Dana Ascherman⁶, Nicole Neiman⁷, Faith Onelangsy⁷, Diane Koontz¹, Kim Goldby-Reffner⁷, Sedin Dzanco⁷, Lei Zhu⁶ and Rohit Aggarwal⁶, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Cedars Sinai Medical Center, Los Angeles, ⁴Attune Health, Los Angeles, ⁵Attune Health, Los Angeles, CA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷UPMC, Pittsburgh
Background/Purpose: There is a paucity of randomized, controlled clinical trials in myositis. Subject enrollment and retention in clinical trials for this rare, heterogeneous disease has…
Abstract Number: 1917 • ACR Convergence 2020
In Myositis Patients, Sjögren’s Syndrome Is Associated with Inclusion Body Myositis and with anti-cN1A Antibody Independently of the Myositis Subgroups
Dan Lévy¹, Benoit Nespola², Margherita Giannini³, Renaud Felten⁴, Francois Severac³, Coralie Varoquier³, Marina Rinagel³, Anne-Sophie Korganow⁵, Vincent Poindron⁵, Thierry Martin⁵, Julien Campagne⁶, Hassam Chereih⁷, Bastien Bouldoires⁸, Baptiste Hervier⁹, Cédric Lenormand³, Emmanuel Chatelus³, Laurent Arnaud¹⁰, Bernard Gény³, Jean Sibilia⁴, Jacques-Eric Gottenberg¹¹ and Alain Meyer¹², ¹CHU Strasbourg, CH, ²Department of Immunobiology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³CHU Strasbourg, Strasbourg, ⁴Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, France, ⁵Department of Clinical Immunology and Internal Medicine, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁶Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, ⁷CH Pontarlier, Pontarlier, ⁸HP Colmar, Colmar, ⁹APHP Paris, Paris, ¹⁰Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, ¹¹Strasbourg University Hospital, Strasbourg, France, ¹²Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France
Background/Purpose: Myositis are characterized by weakness and muscle inflammation. They encompass heterogeneous conditions, which include dermatomyositis (DM), inclusion body myositis (IBM) and polymyositis (PM) according…
Abstract Number: 1068 • ACR Convergence 2020
Efficacy of Early Initiation of Plasma Exchange Therapy for a Patient with Anti-MDA5 Autoantibody-Positive Dermatomyositis Developing Refractory Rapidly Progressive Interstitial Lung Disease
Noriko Sasaki¹, Akira Ishii¹, Keigo Shimura¹, Azusa Kojima¹, Mai Sugiyama², Yuto Izumi¹, Kazuki Hirano¹, Sho Sasaki², Takayoshi Kurabayashi¹, Yuji Hosono², Chiho Yamada² and Shinji Sato², ¹Tokai University School of Medicine, Isehara, Kanagawa, Japan, ²Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Dermatomyositis (DM), and particularly the subtype clinically amyopathic DM (CADM), is often associated with fatal rapidly progressive interstitial lung disease (RP-ILD) when anti-melanoma differentiation-associated…
Abstract Number: 1090 • ACR Convergence 2020
Abnormal HDL Antioxidant Function Is Associated with Longitudinal Change in Lung Physiology in Dermatomyositis/Polymyositis Associated Lung Disease
Sangmee Bae¹, Jennifer Wang¹, Ani Shahbazian² and Christina Charles-Schoeman², ¹University of California Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with dermatomyositis (DM) and polymyositis (PM). We previously reported abnormal anti-oxidant function…
Abstract Number: 1989 • ACR Convergence 2020
NXP2 Autoantibodies Link to Interferon Signature in Juvenile Myositis Lesional Skin
Jessica Turnier¹, Lauren Pachman², Lori Lowe³, Alex Tsoi³, Sultan Elhaj¹, Rajasree Menon¹, Maria Amoruso², Gabrielle Morgan⁴, Johann Gudjonsson⁵, Celine Berthier³ and J Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Michigan, Ann Arbor, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Michigan, Ann ArborUniversity of Michigan
Background/Purpose: Skin inflammation can herald systemic disease in juvenile myositis (JM), yet we lack an understanding of pathogenic mechanisms driving skin inflammation in JM. The…
Abstract Number: 1069 • ACR Convergence 2020
Scleromyositis Is Associated with Nailfold Capillary Abnormalities Compared to Immune-Mediated Necrotizing Myopathy
Océane Landon-Cardinal¹, Valérie Leclair², Yves Troyanov³, Martial Koenig⁴, Alain Meyer⁵, Sabrina Hoa¹, Josiane Bourré-Tessier¹, Isabelle Ferdinand⁶, Jason Karamchandani⁷, Erin O'Ferrall⁸, Minoru Satoh⁹, Marvin Fritzler¹⁰, Benjamin Ellezam¹¹, Jean-Luc Senécal¹, Marie Hudson² and Geneviève Gyger², ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ⁴Division of Internal Medicine, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁵Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁶Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁷Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis associated with features of systemic sclerosis (SSc) and characterized by prominent vasculopathic features on ultrastructural…
Abstract Number: 1091 • ACR Convergence 2020
A Computer-Aided Diagnostic System for Quantitative Scoring of Extent of Interstitial Lung Disease (ILD) in Dermatomyositis/Polymyositis Associated ILD
Sangmee Bae¹, Andrea Oh², Grace Kim³, Jonathan Goldin³ and Christina Charles-Schoeman⁴, ¹University of California Los Angeles, Los Angeles, CA, ²National Jewish Health, Denver, CO, ³University of California, Los Angeles, Los Angeles, ⁴University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) occurs in up to 80% of patients with dermatomyositis (DM) and polymyositis (PM), and is a leading cause of morbidity…
Abstract Number: 1990 • ACR Convergence 2020
Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Lylan Bergeron², Samantha Dill², Michelle O'Brien², Laura Vian³, Minal Jain⁴, Manuk Manukyan², Xiaobai Li⁵, Shajia Lu³, Wanxia L. Tsai³, Kalyani Mishra Thakur⁶, Yinghui Shi⁶, Massimo Gadina⁷, April Brundidge², Michelle Millwood², Lisa G. Rider⁸ and Robert Colbert², ¹Juvenile Myositis Pathogenesis and Therapeutics Unit / NIAMS / National Institutes of Health, Bethesda, MD, ²Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ³Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁴Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁵Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, ⁶Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 0085 • ACR Convergence 2020
Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition
Fadi Charouf¹, Netanel Karbian¹, Itamar Altman¹, Yakov Fellig¹ and Dror Mevorach¹, ¹Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…
Abstract Number: 1070 • ACR Convergence 2020
Scleromyositis Is Associated with Distinct Muscle Vasculopathic Features
Océane Landon-Cardinal¹, Valérie Leclair², Yves Troyanov³, Alain Meyer⁴, Sabrina Hoa¹, Josiane Bourré-Tessier¹, Valérie Nadon⁵, Julie Drouin⁶, Jason Karamchandani⁷, Erin O'Ferrall⁸, Minoru Satoh⁹, Marvin Fritzler¹⁰, Jean-Luc Senécal¹, Marie Hudson² and Benjamin Ellezam¹¹, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ⁴Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁵Division of Rheumatology, Hôpital Notre-Dame, Montreal, Québec, Canada, Montréal, QC, Canada, ⁶Division of Rheumatology, Centre hospitalier régional de Trois-Rivières, Trois-Rivières, QC, Canada, ⁷Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis (AIM) associated with features of systemic sclerosis (SSc). Muscle biopsy studies are sparse and have…
Abstract Number: 1092 • ACR Convergence 2020
NMR-Based Serum Metabolomics, Is It Different in Clinico-Serological Clusters of Idiopathic Inflammatory Myositis?
Naveen R¹, Anupam Guleria², Dinesh Kumar², Umesh Kumar², Anamika Anuja¹, Vikas Agarwal³ and Latika Gupta⁴, ¹Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Centre of Biomedical Research, Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Post Graduate Institute of Medical Sciences, LUCKNOW, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Idiopathic inflammatory myositis (IIM) are rare and heterogenous. Myositis specific antibodies (MSA) show mutual exclusivity and identify specific clinical phenotypes1. Most biomarker studies are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].